Stock Analysis
West Pharmaceutical Services, Inc. (WST) Stock Analysis
West Pharmaceutical Services, Inc. (WST) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
West Pharmaceutical Services, Inc. (WST) currently has an AIQ Score of 60/100, indicating a neutral setup. Momentum is the strongest factor at 87/100. Value is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
WST at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $412.62 |
| AIQ Score | 60/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $23.83B |
| P/E Ratio (TTM) | 43.03 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $2.17 |
| Revenue (quarter ended 2026-06-30) | $872.3M |
| Dividend Yield (TTM) | 0.26% |
| Beta | 1.14 |
| Volume | 1.06M |
| 52-week range | $223.83-$438.27 |
| RSI 14 | 82.79 |
| 50-Day SMA | $366.43 |
| 200-Day SMA | $312.69 |
| Analyst Price Target | $410.22 |
| Next Earnings | Feb 11, 2027 |
WSTWest Pharmaceutical Services, Inc.
Healthcare / Medical - Instruments & Supplies
Low Priority
Above Peers
Latest quote
- Momentum87
- Value26
- Quality63
- Risk resilience78
- Sentiment—
WST Stock Analysis Summary
West Pharmaceutical Services, Inc. (WST) currently has an AIQ Score of 60/100, indicating a neutral setup. Momentum is the strongest factor at 87/100. Value is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, WST has AIQ Score of 60/100 with Momentum base of 87/100 and fading Value at 26/100. Wait for component alignment before adding exposure.
Momentum (87/100) leads while Value (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.97% stock move · WST classified in Medical - Instruments & Supplies.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is WST Bullish or Bearish Right Now?
WST currently has a neutral overall setup. Momentum is the strongest factor at 87/100, while Value is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 63/100.
- - Momentum is constructive at 87/100.
- - Risk Resilience is supportive at 78/100.
- - Price is +13.71% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (37 vs 6).
- - Value is the current constraint at 26/100.
- - Analyst target implies -0.58% downside from the latest quote.
Current Consensus
WST's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 2 neutral, and 6 sell votes. WST's 14-day RSI is 82.79, which places the stock in an overbought momentum range. WST's beta is 1.14, indicating market sensitivity broadly in line with the market.
What Changed in WST?
The largest recent change in WST is Momentum moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the WST Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
WST Decision Framework
Public evidence layers, setup checks, and risk context for West Pharmaceutical Services, Inc..
West Pharmaceutical Services, Inc. (WST) Stock Analysis
West Pharmaceutical Services, Inc. has an AIQ Score of 60/100 in a Neutral regime. Momentum is strongest at 87/100. Beta is 1.13, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | WST is in a Neutral AIQ regime with score 60/100. |
| Signal Conflict | The primary conflict is that momentum leads at 87/100 while value lags at 26/100. |
| Factor Evidence | Momentum 87/100 · Value 26/100 · Quality 63/100 · Risk 78/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 87/100.
Momentum is 87/100 and RSI (14) is 82.8.
WST is in a Neutral regime at 60/100.
Risk factor is 78/100 with beta 1.13 and annual volatility 31.41%.
Current conflict: momentum leads at 87/100 while value lags at 26/100.
WST Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
WST Fundamentals
WST valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
WST Technical Analysis
WST technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
WST Stock Catalysts
Track WST earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
WST Dividend Analysis
WST dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
WST Financial Data
WST revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
WST Risk Analysis
WST volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
WST Stock News
WST stock news, market tone, recent headlines, and catalyst context.
WST vs Industrial Machinery & Equipment Peers
Current peer cohort: WST · XYL · ALLE · AME · AOS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| WST Current stock | 60/100 | 26/100 | 87/100 | 78/100 | 1.25 | 31.41% | Current |
| XYL Xylem | 47/100 | 59/100 | 21/100 | 56/100 | -1.75 | 29.56% | WST vs XYL |
| ALLE Allegion | 68/100 | 54/100 | 89/100 | 57/100 | 0.43 | 29.78% | WST vs ALLE |
| AME AMETEK | 56/100 | 39/100 | 65/100 | 69/100 | 1.27 | 23.91% | WST vs AME |
| AOS A.O. Smith | 70/100 | 66/100 | 80/100 | 63/100 | -0.12 | 27.55% | WST vs AOS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching WST
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for WST
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
WST Stock FAQ
What is WST stock price today?
West Pharmaceutical Services, Inc.'s current stock price is $412.62. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is WST bullish or bearish right now?
WST's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is WST's market cap?
WST's market cap is $23.83B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is WST's current P/E ratio?
WST's current P/E ratio is 43.03 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is WST's RSI?
WST's 14-day RSI is 82.79 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is WST above its 50-day and 200-day moving averages?
WST is 13.71% from its 50-day SMA and 33.25% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is WST's next earnings date?
WST's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does WST pay a dividend?
WST's dividend yield is 0.26% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.